Long-term Effect of Dupilumab in N-ERD

Inclusion Criteria: * Participated previously in our preliminary study (EK 1044/2020) and continued Dupilumab treatment since then. Long-term use of Dupilumab since the preliminary study will be assessed based on patient self-report, as there is currently no clinical test or laboratory parameter available to objectively verify treatment duration. * Signed and dated informed consent has been obtained * Current therapy with Dupilumab Exclusion Criteria: * Pregnancy (as determined by urine ß-HCG test) * Clinically significant abnormal laboratory values and active infection (Tbc, HIV, hepatitis A/B/C) * History of malignancy or immunodeficiency * Chronic obstructive lung disorders (COPD), other obstructive lung disorders (bronchiolitis) * Need for systemic corticosteroid therapy 1 month prior to screening visit * Eosinophilic pneumonia and Churg-Strauss Syndrome * Previous anaphylaxis and contraindications against ASA as outlined in the official prescribing information.